High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial-Reference-Cited by-同舟云学术

High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial

Published:2016-06 Issue:3 Volume:71 Page:309-316
ISSN:0001-5385
Container-title:Acta Cardiologica
language:en
Short-container-title:Acta Cardiologica

Author:

Zhang Yunmei¹,Zhao Yan¹,Pang Mingjie¹,Wu Yongxin¹,Zhuang Ke¹,Zhang Hong¹,Bhat Amit²

Affiliation:

1. Department of Cardiology, People’s First Hospital of Yunnan Province, Kunming, Yunnan, China

2. Medical Services, Indegene Lifesystems Pvt Ltd, Bangalore, Karnataka, India.

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/AC.71.3.3152091

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of the prasugrel, ticagrelor, and clopidogrel dual antiplatelet therapies following an acute coronary syndrome: A systematic review and Bayesian network meta-analysis;2023-08-16

2. Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs;Current Cardiovascular Risk Reports;2023-01-10

3. Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention;Trends in Cardiovascular Medicine;2021-12

4. Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events;Stroke;2021-09

5. A review of the effects of ticagrelor on adenosine concentration and its clinical significance;Pharmacological Reports;2021-07-20